Indications

M-M-R®II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

The ACIP recommends administration of the first dose of M-M-R®II at 12 to 15 months of age and administration of the second dose of M-M-R®II at 4 to 6 years of age.

Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic or anaphylactoid reaction to neomycin; blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems; primary or acquired immunodeficiency conditions; family history of congenital or hereditary immunodeficiency or receiving immunosuppressive therapy; an active febrile illness; or those who are pregnant. If vaccination of postpubertal females is undertaken, pregnancy should be avoided for 3 months following vaccination.

Due caution should be employed in administration of M-M-R®II to persons with: a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided; anaphylaxis or immediate hypersensitivity to eggs; thrombocytopenia.

The following adverse reactions have been reported with M-M-R®II without regard to causality: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, and thrombocytopenia. Additional adverse reactions, which have been reported without regard to causality, include encephalitis and encephalopathy in their diverse clinical presentations.

Vaccination should be deferred for 3 months or longer following blood or plasma transfusions, or administration of immune globulin (human).

As for any vaccine, vaccination with M-M-R®II may not result in protection in 100% of vaccinees.

Dosage and Administration

FOR SUBCUTANEOUS ADMINISTRATION. Do not inject intravascularly.

Immune globulin (IG) is not to be given concurrently with M-M-R®II.

M-M-R®II should be given one month before or after administration of other live viral vaccines. M-M-R®II has been administered concurrently with VARIVAX® (Varicella Virus Vaccine Live) and PedvaxHIB® [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] using separate injection sites and syringes.

Before administering M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live), please read the Prescribing Information. The Patient Information also is available.

1. Centers for Disease Control and Prevention (CDC). Vaccine Storage & Handling Toolkit. http://www.cdc.gov/vaccines/hcp/admin/storage/
toolkit/storage-handling-toolkit.pdf. Published June 2016. Accessed March 24, 2017.
2. Centers for Disease Control and Prevention (CDC). Milestones in the history of vaccination. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th rev ed. Washington, DC: Public Health Foundation; 2015:ii–xi.
3. Food and Drug Administration (FDA). Center for
Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of licensure of ProQuad™. http://www.fda.gov/downloads/
biologicsbloodvaccines/vaccines/
approvedproducts/ucm123800.pdf. Effective August 26, 2005. Accessed March 24, 2017.
4. Centers for Disease Control and Prevention (CDC). Recommended immunization schedule for children and adolescents aged 18 years or younger, United States, 2017. https://www.cdc.gov/vaccines/schedules/downloads/
child/0-18yrs-child-combined-schedule.pdf. Effective January 1, 2017. Accessed March 24, 2017.

Seroconversion Rates

In clinical trials, M-M-R®II demonstrated high seroconversion rates after the first dose

Seroconversion Banner Image

95%
MEASLES

96%
MUMPS

99%
RUBELLA

Seroconversion Banner Image

95%
MEASLES

96%
MUMPS

99%
RUBELLA

Study Design: Clinical studies of 284 triple-seronegative children 11 months to 7 years of age demonstrated that M-M-R®II is highly immunogenic.

Indications

M-M-R®II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.

The ACIP recommends administration of the first dose of M-M-R®II at 12 to 15 months of age and administration of the second dose of M-M-R®II at 4 to 6 years of age.

Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic or anaphylactoid reaction to neomycin; blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems; primary or acquired immunodeficiency conditions; family history of congenital or hereditary immunodeficiency or receiving immunosuppressive therapy; an active febrile illness; or those who are pregnant. If vaccination of postpubertal females is undertaken, pregnancy should be avoided for 3 months following vaccination.

Due caution should be employed in administration of M-M-R®II to persons with: a history of cerebral injury, individual or family histories of convulsions, or any other condition in which stress due to fever should be avoided; anaphylaxis or immediate hypersensitivity to eggs; thrombocytopenia.

The following adverse reactions have been reported with M-M-R®II without regard to causality: fever, headache, dizziness, rash, injection-site reactions, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, and thrombocytopenia. Additional adverse reactions, which have been reported without regard to causality, include encephalitis and encephalopathy in their diverse clinical presentations.

Vaccination should be deferred for 3 months or longer following blood or plasma transfusions, or administration of immune globulin (human).

As for any vaccine, vaccination with M-M-R®II may not result in protection in 100% of vaccinees.

Dosage and Administration

FOR SUBCUTANEOUS ADMINISTRATION. Do not inject intravascularly.

Immune globulin (IG) is not to be given concurrently with M-M-R®II.

M-M-R®II should be given one month before or after administration of other live viral vaccines. M-M-R®II has been administered concurrently with VARIVAX® (Varicella Virus Vaccine Live) and PedvaxHIB® [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] using separate injection sites and syringes.

Before administering M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live), please read the Prescribing Information. The Patient Information also is available.

VACC-1159574-0004 09/17